Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, et al.
Cancer Discovery (2017) Vol. 7, Iss. 7, pp. 675-693
Open Access | Times Cited: 577

Showing 1-25 of 577 citing articles:

Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1287
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das, Douglas B. Johnson
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 857
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Dan Sha, Zhaohui Jin, Jan Budczies, et al.
Cancer Discovery (2020) Vol. 10, Iss. 12, pp. 1808-1825
Open Access | Times Cited: 579
A decade of clinical development of PARP inhibitors in perspective
Joaquı́n Mateo, Christopher J. Lord, Violeta Serra, et al.
Annals of Oncology (2019) Vol. 30, Iss. 9, pp. 1437-1447
Open Access | Times Cited: 555
Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan‐Tong Liu, Zhi‐Jun Sun
Theranostics (2021) Vol. 11, Iss. 11, pp. 5365-5386
Open Access | Times Cited: 509
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 17, pp. 1685-1694
Open Access | Times Cited: 457
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 389-402
Open Access | Times Cited: 412
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson, Chaitanya Bandlamudi, Michael L. Cheng, et al.
Nature (2019) Vol. 571, Iss. 7766, pp. 576-579
Open Access | Times Cited: 349
T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan Trujillo, Randy F. Sweis, Riyue Bao, et al.
Cancer Immunology Research (2018) Vol. 6, Iss. 9, pp. 990-1000
Open Access | Times Cited: 340
The Immunoscore: Colon Cancer and Beyond
Helen K. Angell, Daniela Bruni, J. Carl Barrett, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 2, pp. 332-339
Closed Access | Times Cited: 323
Current status and future directions of cancer immunotherapy
Hongming Zhang, Jibei Chen
Journal of Cancer (2018) Vol. 9, Iss. 10, pp. 1773-1781
Open Access | Times Cited: 320
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra, Giulia Viale, Giuseppe Curigliano
BMC Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 319
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3759-3771
Open Access | Times Cited: 289
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer
Chun-Chin Chen, Weiran Feng, Pei Xin Lim, et al.
Annual Review of Cancer Biology (2017) Vol. 2, Iss. 1, pp. 313-336
Open Access | Times Cited: 284
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
David Tamborero, Carlota Rubio-Pérez, Ferran Muiños, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3717-3728
Open Access | Times Cited: 271
DNA damage and genome instability by G-quadruplex ligands are mediated by R loops in human cancer cells
Alessio De Magis, Stefano Giustino Manzo, Marco Russo, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 116, Iss. 3, pp. 816-825
Open Access | Times Cited: 269
PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 3, pp. 1211-1228
Open Access | Times Cited: 265
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Davide Ciardiello, Pietro Paolo Vitiello, Claudia Cardone, et al.
Cancer Treatment Reviews (2019) Vol. 76, pp. 22-32
Open Access | Times Cited: 262
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai, David J. VanderWeele, Ravi A. Madan, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 260
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Antonio Marra, Dario Trapani, Giulia Viale, et al.
npj Breast Cancer (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 254
Ovarian Cancer Immunotherapy and Personalized Medicine
Susan Morand, Monika Devanaboyina, Hannah Staats, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6532-6532
Open Access | Times Cited: 242
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
Chengming Liu, Sufei Zheng, Runsen Jin, et al.
Cancer Letters (2019) Vol. 470, pp. 95-105
Open Access | Times Cited: 238
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Jung-Mao Hsu, Chia‐Wei Li, Y.‐H. LAI, et al.
Cancer Research (2018) Vol. 78, Iss. 22, pp. 6349-6353
Open Access | Times Cited: 230
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 11, pp. 701-717
Closed Access | Times Cited: 211
Cancer immunotherapy: broadening the scope of targetable tumours
Jitske van den Bulk, Els M.E. Verdegaal, Noel F.C.C. de Miranda
Open Biology (2018) Vol. 8, Iss. 6
Open Access | Times Cited: 209
Page 1 - Next Page

Scroll to top